Lifeboat Foundation

Last year, the pharmaceutical company Biogen released a drug called Aduhelm. It was the first new Alzheimer’s drug approved by the FDA in almost 20 years, but its rollout was mired in controversy — vast swaths of experts decried its approval, claiming there simply wasn’t enough evidence to support its efficacy, while the Journal of American Medicine (JAMA) rejected Biogen’s key Aduhelm paper. Shortly thereafter, Medicare chose to limit coverage of the drug.

All that is to say that given last year’s Aduhelm spectacle, you’d be forgiven for doubting what appears to be a promising development in Biogen’s continued Alzheimer’s drug development. And that’s just what it announced with a collaborator, fellow pharmaceutical maker Eisai, on Tuesday. But that being said, initial data suggests that the new drug is actually proving quite successful in late-stage clinical trials — enough so that Biogen might have a redemption arc, after all.

That new drug, lecanemab, is an anti-amyloid medication. An amyloid is a type of protein, and a normal one for brains to produce. An overabundance of amyloids, however, is believed to be caused by a disruption in a healthy brain’s built-in protein disposal system, resulting in a plaque; although our understanding is still fuzzy, brains with Alzheimer’s are shown to have abnormal plaque levels, so the idea is that anti-amyloid lecenameb, administered intravenously, could scrub that plaque away.

Rates of anxiety and depression have been increasing around the world for decades, a trend that has been sharply exacerbated by the COVID-19 pandemic. New research led by the Boyce Thompson Institute’s Frank Schroeder could ultimately lead to new therapeutics to help relieve this global mental health burden.

First discovered in the 1930s, serotonin is a neurotransmitter produced in many animals that mediates myriad behaviors, such as feeding, sleep, mood and cognition. Drugs that alter serotonin levels are the main weapon to treat psychological conditions like anxiety and depression, as well as eating disorders.

As a simple model for neurobiology research, the microscopic roundworm Caenorhabditis elegans has been used extensively to study serotonin’s role in regulating behavior and food intake. For many years, researchers thought that serotonin was made in C. elegans by one specific molecular pathway, and that serotonin was then quickly degraded. Schroeder’s team and colleagues at Columbia University now demonstrated that both of those assumptions were not quite correct.

Reach out right now and touch anything around you. Whether it was the wood of your desk, a key on your keyboard, or the fur of your dog, you felt it the instant your finger contacted it.

Or did you?

In actuality, takes a bit of time for your brain to register the sensation from your fingertip. However, it does still happen extremely fast, with the touch signal traveling through your nerves at over 100 miles per hour. In fact, some nerve signals are even faster, approaching speeds of 300 miles per hour.

In Scientists were, for the first time, able to show that 800,000 living brain cells trapped in a petri dish can be taught how to play the videogame Pong.

When lab-grown clumps of human neurons are transplanted into newborn rats, they grow with the animals. The research raises some tricky ethical questions.

The DishBrain system was developed to leverage neuronal computation and interact with neurons embodied in a simulated environment (STAR Methods; Figure 4 A; Video S2). The DishBrain environment is a low-latency, real-time system that interacts with the vendor MaxOne software, allowing it to be used in ways that extend its original functions (Figure 4 B). This system can record electrical activity in a neuronal culture and provide “sensory” (non-invasive) electrical stimulation comparably to the generation of action potentials by activity in the neuronal network (

Toward the neurocomputer: image Processing and pattern recognition with neuronal cultures.

Australian and UK researchers grow brain cells in a lab that have learned to play a 1970s video game.

Scientists have transplanted human brain cells into the brains of baby rats, where the cells grew and formed connections.

It’s part of an effort to better study human brain development and diseases affecting this most complex of organs, which makes us who we are but has long been shrouded in mystery.

“Many disorders such as autism and schizophrenia are likely uniquely human” but “the human brain certainly has not been very accessible,” said said Dr. Sergiu Pasca, senior author of a study describing the work, published Wednesday in the journal Nature.

Rat–human hybrid brains offer new ways to study human neuro disorders, but also raise ethical questions.